101 related articles for article (PubMed ID: 16481037)
1. Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl.
Dasmahapatra G; Nguyen TK; Dent P; Grant S
Leuk Res; 2006 Oct; 30(10):1263-72. PubMed ID: 16481037
[TBL] [Abstract][Full Text] [Related]
2. Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.
Chandra J; Tracy J; Loegering D; Flatten K; Verstovsek S; Beran M; Gorre M; Estrov Z; Donato N; Talpaz M; Sawyers C; Bhalla K; Karp J; Sausville E; Kaufmann SH
Blood; 2006 Mar; 107(6):2501-6. PubMed ID: 16291594
[TBL] [Abstract][Full Text] [Related]
3. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
Yu C; Rahmani M; Conrad D; Subler M; Dent P; Grant S
Blood; 2003 Nov; 102(10):3765-74. PubMed ID: 12893773
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
Dai Y; Rahmani M; Pei XY; Dent P; Grant S
Blood; 2004 Jul; 104(2):509-18. PubMed ID: 15039284
[TBL] [Abstract][Full Text] [Related]
5. Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines.
Barnes DJ; De S; van Hensbergen P; Moravcsik E; Melo JV
Leukemia; 2007 Mar; 21(3):421-6. PubMed ID: 17252018
[TBL] [Abstract][Full Text] [Related]
6. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro.
Mow BM; Chandra J; Svingen PA; Hallgren CG; Weisberg E; Kottke TJ; Narayanan VL; Litzow MR; Griffin JD; Sausville EA; Tefferi A; Kaufmann SH
Blood; 2002 Jan; 99(2):664-71. PubMed ID: 11781252
[TBL] [Abstract][Full Text] [Related]
7. Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma.
Podar K; Raab MS; Tonon G; Sattler M; Barilà D; Zhang J; Tai YT; Yasui H; Raje N; DePinho RA; Hideshima T; Chauhan D; Anderson KC
Cancer Res; 2007 Feb; 67(4):1680-8. PubMed ID: 17308109
[TBL] [Abstract][Full Text] [Related]
8. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.
Gatto S; Scappini B; Pham L; Onida F; Milella M; Ball G; Ricci C; Divoky V; Verstovsek S; Kantarjian HM; Keating MJ; Cortes-Franco JE; Beran M
Haematologica; 2003 Aug; 88(8):853-63. PubMed ID: 12935973
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl‑dependent mechanisms.
Xu W; Wei W; Yu Q; Wu C; Ye C; Wu Y; Yan H
Mol Med Rep; 2014 Sep; 10(3):1519-24. PubMed ID: 24939418
[TBL] [Abstract][Full Text] [Related]
10. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
11. Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells.
Orsolic N; Golemovic M; Quintás-Cardama A; Scappini B; Manshouri T; Chandra J; Basic I; Giles F; Kantarjian H; Verstovsek S
Cancer Sci; 2006 Sep; 97(9):952-60. PubMed ID: 16822295
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors.
Jagani Z; Song K; Kutok JL; Dewar MR; Melet A; Santos T; Grassian A; Ghaffari S; Wu C; Yeckes-Rodin H; Ren R; Miller K; Khosravi-Far R
Cancer Res; 2009 Aug; 69(16):6546-55. PubMed ID: 19654305
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib and sphingosine kinase inhibitor interact synergistically to induces apoptosis in BCR/ABl+ cells sensitive and resistant to STI571 through down-regulation Mcl-1.
Li QF; Yan J; Zhang K; Yang YF; Xiao FJ; Wu CT; Wang H; Wang LS
Biochem Biophys Res Commun; 2011 Feb; 405(1):31-6. PubMed ID: 21195056
[TBL] [Abstract][Full Text] [Related]
14. An investigation of reversal of imatinib resistance in the Bcr-Abl positive imatinib-resistant cell line K562r by dasatinib, nilotinib, rapamycin and bortezomib.
Xing H; Liu T; Meng W; Gong Y
Int J Lab Hematol; 2011 Apr; 33(2):176-81. PubMed ID: 20942869
[TBL] [Abstract][Full Text] [Related]
15. Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells.
Bucur O; Stancu AL; Goganau I; Petrescu SM; Pennarun B; Bertomeu T; Dewar R; Khosravi-Far R
PLoS One; 2013; 8(10):e77390. PubMed ID: 24155950
[TBL] [Abstract][Full Text] [Related]
16. Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism.
Zhang H; Trachootham D; Lu W; Carew J; Giles FJ; Keating MJ; Arlinghaus RB; Huang P
Leukemia; 2008 Jun; 22(6):1191-9. PubMed ID: 18385754
[TBL] [Abstract][Full Text] [Related]
17. Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells.
Chandra J; Hackbarth J; Le S; Loegering D; Bone N; Bruzek LM; Narayanan VL; Adjei AA; Kay NE; Tefferi A; Karp JE; Sausville EA; Kaufmann SH
Blood; 2003 Dec; 102(13):4512-9. PubMed ID: 12920036
[TBL] [Abstract][Full Text] [Related]
18. The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism.
Dasmahapatra G; Rahmani M; Dent P; Grant S
Blood; 2006 Jan; 107(1):232-40. PubMed ID: 16166589
[TBL] [Abstract][Full Text] [Related]
19. Cleavage of BCR-ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR-ABL leukemic cells.
Kim JE; Yoon S; Choi BR; Kim KP; Cho YH; Jung W; Kim DW; Oh S; Kim DE
Leukemia; 2013 Aug; 27(8):1650-8. PubMed ID: 23434731
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
